Tandem Diabetes Care (NSDQ:TNDM) said today that it launched the t:lock Connector for its insulin pump cartridges and infusion sets. The connector, which is produced and supplied by Unomedical, has a small inner cavity. San Diego-based Tandem said this feature reduces the amount of insulin used while filling an infusion set and lessens the time required […]
Diabetes
Diabetes app developer DarioHealth closes $5m private placements
Digital health company DarioHealth (NSDQ:DRIO) said today that it closed a $5 million private placement with new and existing investors for shares of the company’s common stock and shares of the company’s Series B convertible preferred stock. The Israel-based company said current shareholders accounted for 58% of the securities sold in the offerings. DarioHealth issued […]
Medtronic supply woes buoy insulin device makers
Share prices for makers of insulin management devices got a bump today after Medtronic (NYSE:MDT) reported today that supply problems pushed sales down -1% for its diabetes division. The Fridley, Minn.-based company, which released its fiscal 2018 first-quarter results this morning, posted diabetes revenues of $449 million for the three months ended July 28. The decline was […]
Dexcom touts continuous glucose monitoring for Type II diabetes patients
Dexcom (NSDQ:DXCM) touted data today showing that people with Type II diabetes who are using multiple daily injections of insulin can benefit from the use of continuous glucose monitoring. Those in the 158-patient study using Dexcom’s G4 Platinum CGM system experienced significant A1C reduction and spent more time in target range compared to a control group […]
Tool identifies diabetes patients at risk for severe hypoglycemia
Researchers have developed a tool used to identify diabetes patients who are at-risk for being admitted to the hospital due to severe hypoglycemia, according to a study published today in JAMA Internal Medicine. “Sometimes a person with diabetes is unaware that their blood sugar is dropping and can progress quickly into severe hypoglycemia, which has been […]
IBM partners to identify risk factors for Type I diabetes
IBM (NYSE:IBM) plans to develop and apply machine learning techniques to years of research data in the hopes of identifying factors that trigger the onset of Type I diabetes in children, with the support of JDRF. Scientists at IBM are slated to assess three different data sets using machine learning algorithms to find patterns and factors […]
Novo Nordisk diabetes drug succeeds in late-stage trial
Shares in Novo Nordisk (NYSE:NVO) rose nearly 5% yesterday afternoon after the insulin-maker said that its once-weekly diabetes drug, semaglutide, succeeded in lowering glucose levels in a late-stage trial. The 40-week trial enrolled 1,200 patients and evaluated two dosages of semaglutide in combination with a standard-of-care-drug. The study compared its drug against Eli Lilly‘s (NYSE:LLY) dulaglutide […]
Glytec lands another 510(k) clearance for diabetes management software
Glytec said today that it won a fourth 510(k) clearance from the FDA for its insulin titration software, eGlycemic Management System featuring Glucommander. The latest FDA nod applies to product enhancements derived from user feedback, the Waltham, Mass.-based company said, including a streamlined transition of inpatients from IV to subcutaneous therapy and more robust workflow […]
Tandem launches pivotal trial for predictive insulin pump
Tandem Diabetes Care (NSDQ:TNDM) said today that it enrolled the first patient in an at-home pivotal trial of its t:slim X2 insulin pump combined with the company’s predictive low glucose suspend algorithm. Using DexCom’s G5 mobile continuous glucose monitor and Tandem’s predictive technology, the insulin pump is designed to halt insulin delivery when it predicts low […]
Allegro’s diabetic macular edema trial meets primary endpoint
Privately-held biotech Allegro Ophthalmics said today that its Del Mar Phase IIb stage 2 trial met its primary endpoint. The study assessed Luminate as a sequential therapy or combo therapy in 80 patients with diabetic macular edema. The San Juan Capistrano, Calif.-based company’s Luminate integrin peptide therapy treats neovascular retinal diseases by targeting integrin receptors, […]